One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

Also called NCT04148820

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04148820
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04148820. Randomized; no masking; primary purpose treatment. Start 2019-11-01 (anticipated); primary completion 2021-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
One Versus Twice Daily Administration of Multiple Cardiovascular Agents in Patients With Ischemic Heart Disease
Acronym
ONCE
Condition
Ischemic Heart Disease
Intervention (Drug)
Aspirin, Atorvastatin, Perindopril
Lead sponsor
University of Roma La Sapienza (class: other)

Record details

Record id
cardio:ct-nct04148820
Content hash
a52a9ef97321e74e9e4e4747673d737835f7167f6d1cf5de4be4669475e262c6